Objective: To analyze the effect of sacubitril-valsartan on left ventricular remodeling and NT-
proBNP in heart failure patients with hypertension and reduced ejection fraction. Method: A …

Background The angiotensin receptor-neprilysin inhibitor sacubitril/valsartan is known to
improve outcomes of cardiac death and hospitalization due to heart failure in patients with …

Background: The aim of this study was to observe the effect of Sacubitril/Valsartan on
cardiac function and remodeling in patients with heart failure with reduced ejection fraction …

Sacubitril/valsartan (SV) has been demonstrated to reduce cardiovascular mortality,
hospitalization for heart failure and to induce reverse ventricular remodeling. The present …

Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients affected by heart
failure (HF) with reduced ejection fraction (HFrEF). HF and type 2 diabetes mellitus (T2DM) …

Background Sacubitril/valsartan, the first agent to be approved in a new class of drugs called
angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular …

Background Previous studies and case-series showed improvement in left ventricular (LV)
function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We …

Background: This study sought to determine, in retrospect, the effect of Sacubitril/Valsartan
on the echocardiographic and functional class of ambulatory HFrEF patients taking …

Chronic heart failure (CHF) seriously affects the quality of patients' lives. Sacrubitril/valsartan
is a combination angiotensin receptor-neprilysin inhibitor, a new therapeutic drugs to treat …

Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …